Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.
Jen Hoogenes(McMaster University), Anil Kapoor(People’s University), Aaron R. Hansen(Princess Margaret Cancer Centre), Simon Tanguay(McGill University Health Centre), Naveen S. Basappa, Rodney H. Breau(University of Ottawa), Ricardo Rendon(Dalhousie University), Frédéric Pouliot(Université Laval), Luke T. Lavallée(University of Ottawa), Bimal Bhindi, Georg A. Bjarnason(Sunnybrook Health Science Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Lori Wood(Dalhousie University), Jean‐Baptiste Lattouf(Centre Hospitalier de l’Université de Montréal), Antonio Finelli(University Health Network), Lucas Dean(University of Alberta), Darrel Drachenberg(CancerCare Manitoba), Ranjeeta Mallick(University of Ottawa), Daniel Yick Chin Heng(University of Calgary), Alan So(University of British Columbia)
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
|The Journal of Urology|2019|482
Prevalence, Risk Factors, and Outcomes of Delirium in Mechanically Ventilated Adults*
|Critical Care Medicine|2014|341
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322